COMPARISON OF INVITRO ANTICANCER-DRUG-SCREENING DATA GENERATED WITH A TETRAZOLIUM ASSAY VERSUS A PROTEIN ASSAY AGAINST A DIVERSE PANEL OF HUMAN TUMOR-CELL LINES

被引:899
作者
RUBINSTEIN, LV
SHOEMAKER, RH
PAULL, KD
SIMON, RM
TOSINI, S
SKEHAN, P
SCUDIERO, DA
MONKS, A
BOYD, MR
机构
[1] INFORMAT MANAGEMENT SERV INC,ROCKVILLE,MD
[2] NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892
[3] NCI,FREDERICK CANC RES FACIL,PROGRAM RESOURCES INC,FREDERICK,MD 21701
关键词
D O I
10.1093/jnci/82.13.1113
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The National Cancer Institute (NCI) is implementing a large-scale in vitro drug-screening program that requires a very efficient automated assay of drug effects on tumor cell viability or growth. Many laboratories worldwide have adopted a microculture assay based on metabolic reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). However, because of certain technical advantages to use of the protein-binding dye sulforhodamine B (SRB) in a large-scale screening application, a detailed comparison of data generated by each type of assay was undertaken. The MTT and SRB assays were each used to test 197 compounds, on simultaneous days, against up to 38 human tumor cell lines representing seven major tumor categories. On subsequent days, 38 compounds were retested with the SRB assay and 25 compounds were retested with the MTT assay. For each of these three comparisons, we tabulated the differences between the two assays in the ratios of test group values to control values (T/C) for cell survival; calculated correlation coefficients for various T/C ratios; and estimated the bivariate distribution of the values for IC50 (concentration of drug resulting in T/C values of 50%, or 50% growth inhibition) for the two assays. The results indicate that under the experimental conditions used and within the limits of the data analyses, the assays perform similarly. Because the SRB assay has practical advantages for large-scale screening, however, it has been adopted for routine use in the NCI in vitro antitumor screen. © 1990 Oxford University Press.
引用
收藏
页码:1113 / 1118
页数:6
相关论文
共 12 条
  • [1] ALLEY MC, 1988, CANCER RES, V48, P589
  • [2] BOYD MR, 1989, PRINC PRACT ONCOL, V3, P1
  • [3] MAXIMUM LIKELIHOOD FROM INCOMPLETE DATA VIA EM ALGORITHM
    DEMPSTER, AP
    LAIRD, NM
    RUBIN, DB
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-METHODOLOGICAL, 1977, 39 (01): : 1 - 38
  • [4] Hollander M., 1973, NONPARAMETRIC STAT M, P185
  • [5] MONKS A, 1989, P AM ASSOC CANC RES, V30, P2417
  • [6] DISPLAY AND ANALYSIS OF PATTERNS OF DIFFERENTIAL ACTIVITY OF DRUGS AGAINST HUMAN-TUMOR CELL-LINES - DEVELOPMENT OF MEAN GRAPH AND COMPARE ALGORITHM
    PAULL, KD
    SHOEMAKER, RH
    HODES, L
    MONKS, A
    SCUDIERO, DA
    RUBINSTEIN, L
    PLOWMAN, J
    BOYD, MR
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (14) : 1088 - 1092
  • [7] SCUDIERO DA, 1988, CANCER RES, V48, P4827
  • [8] SHOEMAKER RH, 1988, PREDICTION RESPONSE, P265
  • [9] SKEHAN P, 1989, P AM ASSOC CANC RES, V30, P2436
  • [10] STINSON S, 1989, P AM ASSOC CANC RES, V30, P2439